References
Cravedi P. Rituximab in membranous nephropathy: not all studies are created equal. Nephron. 2017;135:46–50.
Iancu Ferfoglia R, Guimarães-Costa R, Viala K, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst. 2016;21:10–4.
Stork AC, Notermans NC, Vrancken AF, Cornblath DR, van der Pol WL. Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. J Peripher Nerv Syst. 2013;18:189–91.
Terenghi F, Ardolino G, Nobile-Orazio E. Guillain–Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma. J Peripher Nerv Syst. 2007;12:142–3.
Weiss MD, Becker P. Paradoxical worsening of anti-myelin associated glycoprotein polyneuropathy following rituximab. Muscle Nerve. 2014;49:457–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared that no conflict of interest exists.
Human and animal rights statement
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
No identifying information about individuals is included in the paper.
About this article
Cite this article
Galassi, G., Testa, F., Bianchi, F. et al. Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome. CEN Case Rep 6, 215–216 (2017). https://doi.org/10.1007/s13730-017-0264-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-017-0264-3